Gentian Diagnostics ASA (DE:6FK) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Gentian Diagnostics ASA has presented a poster at the ADLM 2024 clinical meeting showcasing their NT-proBNP assay prototype that improves the accuracy of heart failure diagnostics by targeting glycosylation-free regions of the NT-proBNP protein, thereby avoiding the underestimation of NT-proBNP levels common in other assays. Their innovative approach demonstrated strong analytical performance and compatibility with various instruments, offering potential for more reliable heart failure diagnosis and patient management. The company emphasizes the benefits of their assay in terms of availability, cost, and workflow efficiency.
For further insights into DE:6FK stock, check out TipRanks’ Stock Analysis page.
